MannKind reports higher revenue, lower losses in Q3
MannKind Corp. reported a substantial rise in revenue and a shrinking net loss in the third quarter of 2021 on Nov. 9, despite news since the quarter ended that the U.S. Food and Drug Administration will not yet approve a hypertension treatment the company is developing with United Therapeutics. MannKind, a Westlake Village-based biotechnology company Read More →
Read More →MannKind shares drop 18% after FDA says it will pass on new blood pressure drug
Shares of Westlake Village-based MannKind Corp. dropped 18% on Oct. 18, after the U.S. Food and Drug Administration did not approve a hypertension treatment the company is developing with United Therapeutics. In a complete letter response, the FDA declined to approve a new drug application for Tyvasio DPI, a treatment being developed by MannKind and Read More →
Read More →MannKind makes $12.5M pharma buy
MannKind Corp., a biotech company based in Westlake Village, announced Dec. 7 that it has acquired a QrumPharma, a privately held biotech company, in a $12.5 million deal. MannKind has purchased all outstanding capital stock of QrumPharma for $3.5 million in cash and just over 3 million shares of MannKind common stock. At MannKind’s stock Read More →
Read More →Sienna, MannKind stocks move on new trial data
Two Westlake Village biotech companies released new data from product trials, spurring stock moves and presaging capital raises to fund further research and development. Analysts remained optimistic on Sienna Biopharmaceuticals despite an 18 percent drop in the stock June 10, after the company released results from clinical trials of its psoriasis product. Despite the Read More →
Read More →
